12.78

3.40% 0.42

Sellas Life Sciences Group Inc (SLS)

Overview News Price History Option Chain Financials Why SLS Down? Discussions Forecast Stock Split

Sellas Life Sciences Group Inc stock is traded at $12.78, with a volume of 4.38M. It is up +3.40% in the last 24 hours and down -4.56% over the past month. SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Previous Close:

$12.36

Open:

$12.4

24h Volume:

4.38M

Relative Volume:

0.46

Market Cap:

$2.58B

Revenue:

Net Income/Loss:

$-29.46M

P/E Ratio:

-55.98

EPS:

-0.2283

Net Cash Flow:

$-28.17M

1W Performance:

+6.41%

1M Performance:

-4.56%

6M Performance:

+255.99%

1Y Performance:

+724.52%

1-Day Range:

$12.18

$13.00

1-Week Range:

$10.85

$13.00

52-Week Range:

$1.39

$15.88

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Name

Sellas Life Sciences Group Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(646) 200-5278

Address

7 TIMES SQUARE, NEW YORK, NY

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

SLS's Discussions on Twitter

Compare SLS vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SLS Sellas Life Sciences Group Inc	12.78	2.38B	0	-29.46M	-28.17M	-0.2283
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-21-21	Initiated	Cantor Fitzgerald	Overweight
Nov-01-18	Initiated	Oppenheimer	Outperform
Apr-02-18	Initiated	H.C. Wainwright	Buy
Mar-19-18	Upgrade	Maxim Group	Hold → Buy

Sellas Life Sciences Group Inc Stock (SLS) Latest News

Aug 14, 2026

SELLAS Life Sciences Group, Inc. • Robinhood Token Price, SLS Price, Live Charts, and Marketcap - Coinbase

Aug 14, 2026

SLS Stock Flat After-Hours Despite Narrower Per-Share Q2 Loss — Investors Eye End Of GPS Quiet Period - Stocktwits

Aug 14, 2026

SLS Stock Surges Toward Fifth Weekly Rise: CEO Touts GPS As Lifeline For Elderly Patients As Cancer Summit Looms - Stocktwits

Aug 14, 2026

SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS - Stocktwits

Aug 14, 2026

SLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvals - Stocktwits

Aug 14, 2026

Why SELLAS (SLS) Posted a Wider Net Loss but a Narrower Per-Share Loss This Quarter - simplywall.st

Aug 14, 2026

SLS Stock Hits Over 4-Year High: CEO Eyes FDA Talks, ‘Whole Gamut’ Of Cancer Uses For GPS - Stocktwits

Aug 14, 2026

SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results - Stocktwits

Aug 14, 2026

Aug 13, 2026

SLS Stock Tanks Hard: Retail Traders Blame Warrant Holders, 'Flippers' Cashing Out Before AML Catalyst - Stocktwits

Aug 13, 2026

SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes - Stocktwits

Aug 13, 2026

SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout - Stocktwits

Aug 13, 2026

SELLAS Life Sciences Group, Inc. • Robinhood Token (SLS) Price Prediction for 2026 to 2031 - Bybit

Aug 13, 2026

SELLAS Life Sciences seen as a strong buy ahead of key Phase 3 trial results for AML treatment GPS. - Pluang

Aug 13, 2026

This One Data Readout Could Make Or Break Sellas Life Sciences Group - Seeking Alpha

Aug 13, 2026

Aug 12, 2026

Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential - Stocktwits

Aug 12, 2026

Investors Buy High Volume of SELLAS Life Sciences Group Put Options (NASDAQ:SLS) - MarketBeat

Aug 12, 2026

10 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga

Aug 12, 2026

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap UpTime to Buy? - MarketBeat

Aug 12, 2026